Immatics NV (IMTX)

[FACT-MASTER]

On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration. Initially announced on February 20, 2020, the terms of the agreement included a €45 Million (~$50 Million) upfront payment to Immatics and the potential for additional milestone and royalty payments in return for access to two of Immatics’ TCR-T programs. As communicated to Immatics, GSK’s decision was made unrelated to the programs and the progress achieved in the collaboration to date. The termination will be effective on December 26, 2022.

https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89581771/immatics-announces-third-quarter-2022-financial-r

If you go back to this article here (Oct.25/22), had they included Immatics in the article it would have been more definitively clear that GSK was exiting the TCR-T space, imo. Most likely it didn't fit with their business model.

https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/